There are estimates that at least 10,000 patients may unnecessarily have suffered kidney damage due to use of aprotinin during heart surgery. Many patients may have been injected with Trasylol to reduce blood loss during coronary artery bypass (CABG) surgery.
The Food and Drug Administration approved Aprotinin in 1993, a drug marketed by Bayer as Trasylol. Sales of Trasylol over the past several years have escalated to more than $600 million.
Patients undergoing heart surgery are largely unaware if Trasylol was used during their heart surgery. The decision to use aprotinin (Trasylol) was made by a patient's treating doctor.
We realize that most patients have had successful heart surgeries and are concerned that nothing negative happens to their doctors. We are here to make sure that if you have suffered Trasylol kidney damage, stroke or heart failure we will work to hold the responsible drug company accountable.
A recent study, published by the New England Journal of Medicine (NEJM) (2006) reported a connection between Trasylol and increased risk of renal (kidney) failure, myocardial infarction, heart failure or stroke in patients who have had heart surgery.
Aprotinin (Trasylol) affects the way in which blood clots. Trasylol is injected into patients who are undergoing open heart surgery. Excessive bleeding, during and after heart surgery, is a serious complication. Such bleeding exposes patients to multiple risks. Trasylol is primarily used during repeat coronary artery bypass surgery to reduce the amount of bleeding. The amount of blood transfusion required is reduced by using clotting medications including Trasylol.
The NEJM study concluded that 2 other generic drugs are available that are safer and less expensive than Trasylol.
Neither of the generic drugs was associated with increased risk of kidney failure, heart attack or stroke.
The federal Food and Drug Administrations (FDA) Cardiovascular and Renal Drug Advisory Committee met on September 21, 2006 to review recent data regarding the safety of aprotinin. On September 29, 2006, the FDA issued a public health advisory stating that it had learned Bayer failed to disclose a study that Bayer had conducted involving 67,000 patients undergoing heart surgery. Preliminary analysis of the Bayer study suggested that Trasylol use was linked with risk for congestive heart failure, renal failure, stoke and death. Bayer did not disclose the study during the September 21, 2006 Advisory Committee meeting.
If you or a loved one has had open heart surgery and then experienced Trasylol kidney damage, heart failure or stroke, you may be able entitled to money damages. Trasylol attorneys can help evaluate your claim.
We are a Law Firm that is dedicated to helping people who have been affected by Trasylol side effects.
Personal Injury Law Firm
Patients and families nationwide have looked at filing a Trasylol lawsuit based on the often fatal side effects of the drug Trasylol. Currently no Trasylol class action suits have been filed by Fields Law Firm and claims are being made individually.
The lawsuits claim that Bayer, the drug’s manufacturer, was negligent in several ways including:
• marketing [...]
The Trasylol heart surgery drug has increasingly been linked to serious side effects including kidney failure and stroke following bypass surgery. Many patients and families have questioned whether Bayer’s heart medication, also referred to as “Aprotinin“, was used during their procedure. The problem is that without looking at the medical records from the day of [...]
Bayer’s widely used Trasylol heart surgery drug was subject to a recall in 2007 following a study that raised safety concerns. Prior to the recall, Trasylol (also referred to as Aprotinin) was used to help prevent excessive bleeding during open heart surgery. The study reported that Bayer’s heart surgery medication increased the risk of dying [...]
Following a Trasylol recall in 2007, Bayer’s heart surgery drug continued to be used during heart surgery even though cheaper and safer alternative drugs were available. Unfortunately, Trasylol was used until as recently as May 2008.In 1993, Trasylol (also referred to as “aprotinin”) received FDA approval for use in certain types of heart surgeries. Until [...]
Bayer’s problems are growing as they face thousands of potential Trasylol lawsuits following increasing reports of their heart surgery drug’s side effects. Trasylol has recently been linked to a higher risk of kidney failure, heart attack, and death in the five years following a patient undergoing bypass heart surgery. In 1993 Trasylol (Aprotinin) was approved [...]